TY - JOUR
T1 - Surgical care of thoracic malignancies during the COVID-19 pandemic in México
T2 - An expert consensus guideline from the Sociedad Mexicana de Oncología (SMeO) and the Sociedad Mexicana de Cirujanos Torácicos Generales (SMCTG)
AU - Corona-Cruz, Jose
AU - Alba, Enrique Guzmán de
AU - Iñiguez-García, Marco
AU - López-Saucedo, Raúl
AU - Olivares-Torres, Carlos
AU - Rodriguez-Cid, Jeronimo
AU - Salazar-Otaola, Gustavo
AU - Martínez-Said, Héctor
AU - Flores, Raja M.
AU - Arrieta, Oscar
N1 - Publisher Copyright:
© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd
PY - 2020/8/1
Y1 - 2020/8/1
N2 - To date, the impact, timeline and duration of COVID-19 pandemic remains unknown and more than ever it is necessary to provide safe pathways for cancer patients. Multiple triage systems for nonemergent surgical procedures have been published, but potentially curative cancer procedures are essential surgery rather than elective surgery. In the present and future scenario of our country, thoracic oncology teams may have the difficult decision of weighing the utility of surgical intervention against the risk for inadvertent COVID-19 exposure for patients and medical staff. In consequence, traditional pathways of surgical care must be adjusted to reduce the risk of infection and the use of resources. It is recommended that all thoracic cancer patients should be offered treatment according to the accepted standard of care until shortage of services require a progressive reduction in surgical cases. Here, we present a consensus of recommendations discussed by a multidisciplinary panel of experts on thoracic oncology and based on the best available evidence, and hope it will provide a modifiable framework of guidance for local strategy planners in thoracic cancer care services in Mexico. Key points: Significant findings of the study: This article provides recommendations to guarantee the continuity of surgical care for thoracic oncology cases during COVID-19 pandemic, whilst maintaining the safety of patients and medical staff. What this study adds: This guideline is the result of an expert consensus on thoracic surgical oncology with recommendations adapted to medical, economic and social realities of Mexico.
AB - To date, the impact, timeline and duration of COVID-19 pandemic remains unknown and more than ever it is necessary to provide safe pathways for cancer patients. Multiple triage systems for nonemergent surgical procedures have been published, but potentially curative cancer procedures are essential surgery rather than elective surgery. In the present and future scenario of our country, thoracic oncology teams may have the difficult decision of weighing the utility of surgical intervention against the risk for inadvertent COVID-19 exposure for patients and medical staff. In consequence, traditional pathways of surgical care must be adjusted to reduce the risk of infection and the use of resources. It is recommended that all thoracic cancer patients should be offered treatment according to the accepted standard of care until shortage of services require a progressive reduction in surgical cases. Here, we present a consensus of recommendations discussed by a multidisciplinary panel of experts on thoracic oncology and based on the best available evidence, and hope it will provide a modifiable framework of guidance for local strategy planners in thoracic cancer care services in Mexico. Key points: Significant findings of the study: This article provides recommendations to guarantee the continuity of surgical care for thoracic oncology cases during COVID-19 pandemic, whilst maintaining the safety of patients and medical staff. What this study adds: This guideline is the result of an expert consensus on thoracic surgical oncology with recommendations adapted to medical, economic and social realities of Mexico.
KW - COVID-19
KW - lung cancer
KW - surgical oncology
KW - thoracic oncology
KW - thoracic surgery
UR - http://www.scopus.com/inward/record.url?scp=85087626912&partnerID=8YFLogxK
U2 - 10.1111/1759-7714.13546
DO - 10.1111/1759-7714.13546
M3 - Article
C2 - 32627963
AN - SCOPUS:85087626912
SN - 1759-7706
VL - 11
SP - 2370
EP - 2375
JO - Thoracic Cancer
JF - Thoracic Cancer
IS - 8
ER -